Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001054596 | SCV001218939 | pathogenic | Fanconi-Bickel syndrome | 2022-10-01 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with Fanconi-Bickel Syndrome (PMID: 22865906). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 850431). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. This sequence change affects an acceptor splice site in intron 4 of the SLC2A2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SLC2A2 are known to be pathogenic (PMID: 11810292). |
Gene |
RCV002305564 | SCV002599997 | pathogenic | not provided | 2022-04-23 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 22865906) |
Fulgent Genetics, |
RCV005029624 | SCV005661879 | likely pathogenic | Type 2 diabetes mellitus; Fanconi-Bickel syndrome | 2024-02-14 | criteria provided, single submitter | clinical testing |